EUVIMEDEUVIMED entdecken
Crossref

Outcomes in Adult Inflammatory Bowel Disease Clinical Trials: Assessment of Similarity Among Participants with Adolescent-onset and Adult-onset Disease

Joel R Rosh, Dan Turner, Jeffrey S Hyams, Marla Dubinsky, Anne M Griffiths iD, Stanley A Cohen, Kim Hung Lo, Lilianne Kim, Sheri Volger, Renping Zhang, Richard Strauss, Laurie S Conklin

Journal of Crohn's and Colitis · 2024

DOI: 10.1093/ecco-jcc/jjae030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Crohn's and Colitis, 2024. Verfasst von Joel R Rosh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Gastroenterology, Cohen Children's Medical Center, New Hyde Park, NY, USA. Hauptthemen laut MEDLINE: Age of Onset, Crohn Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Johnson & Johnson Innovative Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Most paediatric inflammatory bowel disease [IBD] studies are performed after medications are approved in adults, and the majority of participants in these studies are adolescents. We hypothesised that adolescent-onset IBD is not fundamentally different from adult-onset IBD. If this is correct, the value of delaying access to novel drugs in adolescents becomes questioned.

Methods

Data from 11 randomised, double-blind, placebo-controlled, adult Phases 2 and 3 trials of four biologics were analysed. Participants were categorised as having adolescent- or adult-onset disease [diagnosed 12 to <18, or ≥18 years]. Multivariable modelling explored the association between age at diagnosis and response to treatment, after adjustment for disease duration, extent, and severity at baseline. Data from dose arms were pooled to evaluate similarity of therapeutic response between adolescent- and adult-onset IBD within the same trial [not between doses or across trials]. Ratios of odds ratios [ORs] between the two groups were evaluated.

Results

Data from 6283 study participants (2575 with Crohn’s disease [CD], 3708 with ulcerative colitis [UC]) were evaluated. Of 2575 study participants with CD, 325 were 12–<18 years old at diagnosis; 836 participants [32.4%] received placebo. Of 3708 participants with UC, 221 were 12–<18 years old at diagnosis; 1212 [33%] were receiving placebo. The majority of the ratios of ORs were within 2-fold, suggesting that responses in adolescent- and adult-onset participants are generally similar.

Conclusion

Data presented lend support for extrapolating efficacy of biologics from adults to adolescents with IBD, which would facilitate earlier labelling and patient access.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Age of OnsetCrohn DiseaseHumansAdolescentAdultFemaleMaleColitis, UlcerativeRandomized Controlled Trials as TopicYoung AdultInfliximabAdalimumabInflammatory Bowel DiseasesGastrointestinal AgentsChildTreatment OutcomeDouble-Blind MethodAntibodies, Monoclonal, HumanizedBiological ProductsClinical Trials, Phase III as TopicAntibodies, Monoclonal

Stichwörter der Autor:innen

Crohn’s diseasePaediatricbiologicsextrapolationulcerative colitis

Substanzen

InfliximabAdalimumabGastrointestinal AgentsgolimumabAntibodies, Monoclonal, HumanizedBiological ProductsvedolizumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Division of Pediatric Gastroenterology, Cohen Children's Medical Center, New Hyde Park, NY, USA.
  • Juliet Keidan Institute of Pediatric Gastroenterology, Shaare Zedek Medical Center, Hebrew University of Jerusalem, Israel.
  • Division of Pediatric Gastroenterology, Connecticut Children's, Hartford, CT, USA.
  • Division of Pediatric Gastroenterology, Mount Sinai Medical Center, New York, NY, USA.
  • Division of Pediatric Gastroenterology, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
  • Division of Pediatric Gastroenterology, Children's Center for Digestive Health Care, Atlanta, GA, USA.

ORCID-Profile: Anne M Griffiths

Förderung

  • Johnson & Johnson Innovative Medicine

Zitieren

APA

Rosh, J. R., Turner, D., Hyams, J. S., Dubinsky, M., Griffiths, A. M., Cohen, S. A., Hung Lo, K., Kim, L., Volger, S., Zhang, R., Strauss, R., & Conklin, L. S. (2024). Outcomes in Adult Inflammatory Bowel Disease Clinical Trials: Assessment of Similarity Among Participants with Adolescent-onset and Adult-onset Disease. Journal of Crohn's and Colitis. https://doi.org/10.1093/ecco-jcc/jjae030

Vancouver

Rosh JR, Turner D, Hyams JS, Dubinsky M, Griffiths AM, Cohen SA, et al. Outcomes in Adult Inflammatory Bowel Disease Clinical Trials: Assessment of Similarity Among Participants with Adolescent-onset and Adult-onset Disease. Journal of Crohn's and Colitis. 2024. doi:10.1093/ecco-jcc/jjae030

BibTeX
@article{Rosh2024,
  author = {Rosh, Joel R and Turner, Dan and Hyams, Jeffrey S and Dubinsky, Marla and Griffiths, Anne M and Cohen, Stanley A and Hung Lo, Kim and Kim, Lilianne and Volger, Sheri and Zhang, Renping and Strauss, Richard and Conklin, Laurie S},
  title = {Outcomes in Adult Inflammatory Bowel Disease Clinical Trials: Assessment of Similarity Among Participants with Adolescent-onset and Adult-onset Disease},
  journal = {Journal of Crohn's and Colitis},
  year = {2024},
  doi = {10.1093/ecco-jcc/jjae030}
}
Kostenlos starten →